Christoph U. Correll, MD

Professor of Psychiatry and Molecular Medicine
The Zucker Hillside Hospital, Glen Oaks, NY, USA; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; Charité Universitätsmedizin Berlin, Berlin, Germany

Poster(s):

• (60) Valbenazine improves the impacts and symptoms of tardive dyskinesia: results from the phase 4 kinect-pro study
  Wednesday, October 29, 2025

• (268) Economic impact of experiential negative symptoms among patients living with schizophrenia: Medical expenditure panel survey
  Wednesday, October 29, 2025

• (347) Estimation of the minimal clinically important difference (MCID) and longitudinal change in the tardive dyskinesia impact scale (TDIS), a validated, tardive dyskinesia-specific, patient-reported outcome measure
  Wednesday, October 29, 2025